CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 4 enrolled
Drug / intervention
zoledronic aciddrug
Likely dose
zoledronic acid 4 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00264420
NCT00264420Phase 1Completed
CompareCT.gov

A Phase I Pilot Trial to Study the Safety and Efficacy of Concomitant Radiotherapy and Zoledronic Acid for the Palliation of Bone Metastases From Breast Cancer, Prostate Cancer and Lung Cancer

The Cleveland Clinic·interventional·Posted Dec 12, 2005·Updated Dec 21, 2010

In Brief

A Phase 1 clinical trial evaluating zoledronic acid for Bone Metastases and 3 related conditions. Completed, enrolled 4 participants.

Detailed Summary

Zoledronic acid (Zometa) belongs to a class of drugs called bisphosphonates. Bisphosphonates are used in bone metastases to keep the cancerous lesion under control in the bone and to help prevent calcium level elevations in the blood. Cancer cell-culture studies at the Cleveland Clinic showed that zoledronic acid and radiation together have more cell killing effect than either one used alone. The purpose of this study is to monitor the healing of bone lesions when using zoledronic acid together with radiation treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBone Metastases, Breast Cancer, Lung Cancer, Prostate Cancer
Countries--
CollaboratorsNovartis

Timeline

Phase 1CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 12, 2005
Enrollment StartDec 1, 2005
Study CompletionMar 1, 2007
TodayJul 2, 2026
Posted 20.6 years ago

Interventions

zoledronic aciddrug

At baseline 4 mg IV zoledronic acid over 15 min. every 4 weeks for 6 months plus radiation therapy 30 Gy in 10 fractions (5 times per week for first two weeks)